A first-in-human phase I study of the CDK4/6 inhibitor, LY2835219, for patients with advanced cancer.

被引：0

作者：

Shapiro, Geoffrey

Rosen, Lee S.

Tolcher, Anthony W.

Goldman, Jonathan Wade

Gandhi, Leena

Papadopoulos, Kyriakos P.

Tolaney, Sara M.

Beeram, Muralidhar

Rasco, Drew Warren

Kulanthaivel, Palaniappan

Li, Qian

Hu, Tianle

Cronier, Damien

Chan, Edward M.

Flaherty, Keith

Wen, Patrick Y.

Patnaik, Amita

机构：

[1] Dana Farber Canc Inst, Boston, MA 02115 USA

[2] Univ Calif Los Angeles, David Geffen Sch Med, Santa Monica, CA USA

[3] START Ctr Canc Care, San Antonio, TX USA

[4] START, San Antonio, TX USA

[5] Eli Lilly & Co, Indianapolis, IN 46285 USA

[6] PharmaNet I3, Indianapolis, IN USA

[7] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2500

引用

页数：1